SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

07 сен 2022 08:55:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022

19 авг 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 авг 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

02 авг 2022 06:00:01 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

15 июл 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day

10 июн 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 июн 2022 06:00:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

26 май 2022 16:15:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors

24 май 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022

16 май 2022 07:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 май 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

19 апр 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

24 фев 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

01 фев 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 янв 2022 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

10 дек 2021 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

06 дек 2021 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

29 ноя 2021 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 ноя 2021 05:30:00 Источник Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

04 ноя 2021 05:30:00 Источник Nasdaq GlobeNewswire